About Certis Above, a 3-dimensional image shows multiple metastatic lesions of lung adenocarcinoma in the liver. Unlike tumors in subcutaneous PDX models, cancer has been shown to metastasize in O-PDX models—one of the many important advantages unique to orthotopic models. Established in 2016, Certis Oncology Solutions is a precision oncology and translational science
Overview: Dr. Lee will discuss how simultaneous PET and MR data acquisition using a fully integrated system, such as the SimPET-M7 simultaneous PET/MRI solution, can provide several advantages over sequential PET/CT for small animal imaging. He will also introduce the SimPET-M7 simultaneous PET/MRI solution for small animal imaging in this talk. Note: That
Overview: Dr. Bogdanov will discuss how multimodality registration of optical and magnetic resonance imaging (MRI) in the same voxels of live tissue could be aided by paramagnetic contrast agents that provide optical clearing (OC) effect. We investigate the effects of gadobutrol (GB) and its combination with DMSO/water as potential OC agent for imaging
Please join us for this 3-part learning mini-series focused on preclinical imaging, presented by Scintica Instrumentation. We will discuss five of the essential imaging technologies used in preclinical research, including optical imaging, high frequency ultrasound, MRI, PET/CT, and fluorescence in vivo endomicroscopy. Please Register for Each Individual Event Below
During this 60-minute webinar, the last part of our preclinical imaging learning mini-series, we discussed the specific imaging systems included in Scintica Instrumentation's imaging product portfolio. While we reviewed the four W’s (what, when, where, why) in our first webinar in this mini-series, this webinar focused on the specific technical capabilities of the products
This was a full day of live imaging where we examined the complimentary nature of three preclinical imaging modalities – bioluminescence, high-frequency ultrasound, and MRI. We imaged the same tumor models on each of the imaging modalities; but will also had normal mouse available to look at cardiovascular function using ultrasound, and brain
Preclinical imaging is greatly enhancing the way researchers and clinicians visualize and understand biological phenomena and various mechanisms of disease in vivo. Slide Deck On Demand Q & A We began this 3-part preclinical imaging learning mini-series with this 60-minute webinar in which
In this webinar presented by Scintica Instrumentation, we took a look at both clinical and preclinical imaging of COVID-19. Starting with a review of current literature surrounding clinical imaging and post-mortem histological autopsy studies of patients with COVID-19, this webinar examined how these studies can inform prospective preclinical investigations using novel imaging
Tumor hypoxia and aerobic glycolysis are well-known resistance factors for anticancer therapies. Most tumour cells are subject to conditions in which oxygen is not readily available, known as tumour hypoxia, due to abnormal vasculature. Effective radiotherapy relies on the creation of reactive oxygen species, therefore hypoxic tumors are radiation resistant. Further, both chemotherapy and
Simultaneous Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) provides a unique non-invasive opportunity to image both the functional and structural characteristics of biological systems. PET imaging shows high-sensitivity to dynamic metabolic and functional processes through tracking of biomarkers in-vivo but lacks the resolution to resolve detailed anatomy. MRI produces exceptional soft-tissue contrast
